| Joshua Laurence Johnson, MD | |
|
1003 Providence Dr, Suite 210, Newberg, OR 97132-7521 | |
| (503) 537-5900 | |
| (503) 537-5959 |
| Full Name | Joshua Laurence Johnson |
|---|---|
| Gender | Male |
| Speciality | Neurology |
| Experience | 25 Years |
| Location | 1003 Providence Dr, Newberg, Oregon |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1659363190 | NPI | - | NPPES |
| 227430 | Medicaid | OR | |
| 8385973 | Medicaid | WA |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sacred Heart Medical Center - Riverbend | Springfield, OR | Hospital |
| Legacy Meridian Park Medical Center | Tualatin, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Legacy Clinics Llc | 0244144004 | 603 |
| Peacehealth | 8527016039 | 174 |
News Archive
Covalon Technologies Ltd., an advanced medical technologies company, today announced that it has licensed its antimicrobial silicone adhesive technology to Molnlycke Heath Care.
Welichem announced that the Company has begun to enroll patients in a Phase IIa clinical trial with its lead candidate, WBI-1001. The Phase IIa clinical trial is a 12-Week, double-blinded, placebo-controlled study. The objectives of the trial are to evaluate the efficacy of the WBI-1001 cream in comparison to the vehicle and also to evaluate the safety and tolerability of the cream in patients with psoriasis.
FibroGen, Inc. (FibroGen) announced today the presentation of clinical data at the American Thoracic Society (ATS) International Conference supporting the safety and efficacy of FG-3019 in patients with idiopathic pulmonary fibrosis (IPF), a debilitating and life-threatening lung disease for which there is currently no approved therapy in the United States.
One class of drug used to treat type 2 diabetes may not reduce the risk of death when compared with placebo, suggests new findings.
GenomeDx Biosciences today announced that the robust Decipher genomic analysis platform, successfully classified various subtypes of bladder cancer based on the genomic expression of certain biomarkers, including one type associated with resistance to cisplatin-based chemotherapy. Importantly, this unique genomic signature has potential as a tool to predict tumor responsiveness to neoadjuvant chemotherapy in patients with muscle-invasive bladder cancers (MIBC).
› Verified 5 days ago
| Entity Name | Legacy Clinics Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902827272 PECOS PAC ID: 0244144004 Enrollment ID: O20031117000089 |
News Archive
Covalon Technologies Ltd., an advanced medical technologies company, today announced that it has licensed its antimicrobial silicone adhesive technology to Molnlycke Heath Care.
Welichem announced that the Company has begun to enroll patients in a Phase IIa clinical trial with its lead candidate, WBI-1001. The Phase IIa clinical trial is a 12-Week, double-blinded, placebo-controlled study. The objectives of the trial are to evaluate the efficacy of the WBI-1001 cream in comparison to the vehicle and also to evaluate the safety and tolerability of the cream in patients with psoriasis.
FibroGen, Inc. (FibroGen) announced today the presentation of clinical data at the American Thoracic Society (ATS) International Conference supporting the safety and efficacy of FG-3019 in patients with idiopathic pulmonary fibrosis (IPF), a debilitating and life-threatening lung disease for which there is currently no approved therapy in the United States.
One class of drug used to treat type 2 diabetes may not reduce the risk of death when compared with placebo, suggests new findings.
GenomeDx Biosciences today announced that the robust Decipher genomic analysis platform, successfully classified various subtypes of bladder cancer based on the genomic expression of certain biomarkers, including one type associated with resistance to cisplatin-based chemotherapy. Importantly, this unique genomic signature has potential as a tool to predict tumor responsiveness to neoadjuvant chemotherapy in patients with muscle-invasive bladder cancers (MIBC).
› Verified 5 days ago
| Entity Name | Silverton Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669424354 PECOS PAC ID: 8921901877 Enrollment ID: O20040129000172 |
News Archive
Covalon Technologies Ltd., an advanced medical technologies company, today announced that it has licensed its antimicrobial silicone adhesive technology to Molnlycke Heath Care.
Welichem announced that the Company has begun to enroll patients in a Phase IIa clinical trial with its lead candidate, WBI-1001. The Phase IIa clinical trial is a 12-Week, double-blinded, placebo-controlled study. The objectives of the trial are to evaluate the efficacy of the WBI-1001 cream in comparison to the vehicle and also to evaluate the safety and tolerability of the cream in patients with psoriasis.
FibroGen, Inc. (FibroGen) announced today the presentation of clinical data at the American Thoracic Society (ATS) International Conference supporting the safety and efficacy of FG-3019 in patients with idiopathic pulmonary fibrosis (IPF), a debilitating and life-threatening lung disease for which there is currently no approved therapy in the United States.
One class of drug used to treat type 2 diabetes may not reduce the risk of death when compared with placebo, suggests new findings.
GenomeDx Biosciences today announced that the robust Decipher genomic analysis platform, successfully classified various subtypes of bladder cancer based on the genomic expression of certain biomarkers, including one type associated with resistance to cisplatin-based chemotherapy. Importantly, this unique genomic signature has potential as a tool to predict tumor responsiveness to neoadjuvant chemotherapy in patients with muscle-invasive bladder cancers (MIBC).
› Verified 5 days ago
| Entity Name | Peacehealth |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740223874 PECOS PAC ID: 8527016039 Enrollment ID: O20050111000353 |
News Archive
Covalon Technologies Ltd., an advanced medical technologies company, today announced that it has licensed its antimicrobial silicone adhesive technology to Molnlycke Heath Care.
Welichem announced that the Company has begun to enroll patients in a Phase IIa clinical trial with its lead candidate, WBI-1001. The Phase IIa clinical trial is a 12-Week, double-blinded, placebo-controlled study. The objectives of the trial are to evaluate the efficacy of the WBI-1001 cream in comparison to the vehicle and also to evaluate the safety and tolerability of the cream in patients with psoriasis.
FibroGen, Inc. (FibroGen) announced today the presentation of clinical data at the American Thoracic Society (ATS) International Conference supporting the safety and efficacy of FG-3019 in patients with idiopathic pulmonary fibrosis (IPF), a debilitating and life-threatening lung disease for which there is currently no approved therapy in the United States.
One class of drug used to treat type 2 diabetes may not reduce the risk of death when compared with placebo, suggests new findings.
GenomeDx Biosciences today announced that the robust Decipher genomic analysis platform, successfully classified various subtypes of bladder cancer based on the genomic expression of certain biomarkers, including one type associated with resistance to cisplatin-based chemotherapy. Importantly, this unique genomic signature has potential as a tool to predict tumor responsiveness to neoadjuvant chemotherapy in patients with muscle-invasive bladder cancers (MIBC).
› Verified 5 days ago
| Entity Name | Virtual Neurology Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760940167 PECOS PAC ID: 9830425321 Enrollment ID: O20210806001385 |
News Archive
Covalon Technologies Ltd., an advanced medical technologies company, today announced that it has licensed its antimicrobial silicone adhesive technology to Molnlycke Heath Care.
Welichem announced that the Company has begun to enroll patients in a Phase IIa clinical trial with its lead candidate, WBI-1001. The Phase IIa clinical trial is a 12-Week, double-blinded, placebo-controlled study. The objectives of the trial are to evaluate the efficacy of the WBI-1001 cream in comparison to the vehicle and also to evaluate the safety and tolerability of the cream in patients with psoriasis.
FibroGen, Inc. (FibroGen) announced today the presentation of clinical data at the American Thoracic Society (ATS) International Conference supporting the safety and efficacy of FG-3019 in patients with idiopathic pulmonary fibrosis (IPF), a debilitating and life-threatening lung disease for which there is currently no approved therapy in the United States.
One class of drug used to treat type 2 diabetes may not reduce the risk of death when compared with placebo, suggests new findings.
GenomeDx Biosciences today announced that the robust Decipher genomic analysis platform, successfully classified various subtypes of bladder cancer based on the genomic expression of certain biomarkers, including one type associated with resistance to cisplatin-based chemotherapy. Importantly, this unique genomic signature has potential as a tool to predict tumor responsiveness to neoadjuvant chemotherapy in patients with muscle-invasive bladder cancers (MIBC).
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joshua Laurence Johnson, MD Po Box 3158, Portland, OR 97208-3158 Ph: () - | Joshua Laurence Johnson, MD 1003 Providence Dr, Suite 210, Newberg, OR 97132-7521 Ph: (503) 537-5900 |
News Archive
Covalon Technologies Ltd., an advanced medical technologies company, today announced that it has licensed its antimicrobial silicone adhesive technology to Molnlycke Heath Care.
Welichem announced that the Company has begun to enroll patients in a Phase IIa clinical trial with its lead candidate, WBI-1001. The Phase IIa clinical trial is a 12-Week, double-blinded, placebo-controlled study. The objectives of the trial are to evaluate the efficacy of the WBI-1001 cream in comparison to the vehicle and also to evaluate the safety and tolerability of the cream in patients with psoriasis.
FibroGen, Inc. (FibroGen) announced today the presentation of clinical data at the American Thoracic Society (ATS) International Conference supporting the safety and efficacy of FG-3019 in patients with idiopathic pulmonary fibrosis (IPF), a debilitating and life-threatening lung disease for which there is currently no approved therapy in the United States.
One class of drug used to treat type 2 diabetes may not reduce the risk of death when compared with placebo, suggests new findings.
GenomeDx Biosciences today announced that the robust Decipher genomic analysis platform, successfully classified various subtypes of bladder cancer based on the genomic expression of certain biomarkers, including one type associated with resistance to cisplatin-based chemotherapy. Importantly, this unique genomic signature has potential as a tool to predict tumor responsiveness to neoadjuvant chemotherapy in patients with muscle-invasive bladder cancers (MIBC).
› Verified 5 days ago
Dr. Isabel Casillas Rosales, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1003 Providence Dr, Suite 110, Newberg, OR 97132 Phone: 503-537-5900 | |
Drew M Houston, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1003 N Providence Dr Ste 210, Newberg, OR 97132 Phone: 503-537-5620 | |
Dr. Keith Henry Griffin, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 33305 Ne Old Parrett Mountain Rd, Newberg, OR 97132 Phone: 503-720-5145 | |
Ellen L Andrae, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1003 Providence Dr, Suite 110, Newberg, OR 97132 Phone: 503-537-5900 | |
Ashutosh Kumar Lodhi, M.D., M.P.H. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1003 Providence Dr, Newberg, OR 97132 Phone: 503-537-5900 | |
Brett Daniel Kaylor, DO Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1000 N Providence Dr Ste 210, Newberg, OR 97132 Phone: 503-537-5900 | |
Dr. Marvin David Seppala, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1901 Esther St, Newberg, OR 97132 Phone: 503-554-4334 |